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Introduction
We live in a time when the words 'impossible ' and 'unsolvable' are Christopher Reeve, Actor, 1999 The above statement is a testament to the faith and the acceptance that the general population has in the development of new technologies, and the role that clinical trials play in testing them, to cure disease. However, this is a recent phenomenon and the path to ensuring that only safe and effective medical devices reach the market has been a long and troubled one.
This book will examine and describe the major changes that have occurred in the regulation of clinical trials and act as a basic guide to how those regulations should be interpreted to create an efficient and successful study of medical devices. The book is aimed to provide a valuable guide to new researchers and a good reference point for experienced researchers, while also providing an insight into the area of clinical trials for anyone involved in producing or marketing medical devices.
The history of medical device legislation and clinical trials
The UK's Select Committee on Patent Medicines stated in 1912 that:
For all practical purposes, British law is powerless to prevent any person from processing any drug or making any mixture, whether patent (or not). Advertising it in any decent terms as a cure for any disease or ailment; recommending it by bogus testimonials and the invented opinion and facsimile signatures of fictitious physicians; and selling it under any name he chooses, on the payment of a small stamp duty for any price he can persuade the credulous public to pay. The Therapeutic Trials Committee will be prepared to consider applications by commercial firms for the examination of new products, submitted with the available experimental evidence of their value, and appropriate clinical trials will be arranged in suitable cases.
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It has been proposed that 1931 was also the year in which the first true randomized trial was conducted. This trial was conducted by Amberson 1 to study the treatment of tuberculosis with sanocrysin on 24 patients who were divided into two groups of equal size on the basis of a coin toss to determine which group would receive sanocrysin and which one the placebo. It was also a blind trial, as none of the patients knew to which group they had been assigned. Prior to 1931, several randomized trials had been reported, but the method of randomization was either not stated or was open to selection bias. For centuries, the structure of clinical testing was shaped by methodological and medical considerations, whereas the concerns of the individuals involved in the studies was of subsidiary importance. The Nuremberg trials drew attention to the unscrupulous experiments inflicted on humans during World War II by the Nazi regime and kindled a worldwide ethical discussion about the performance of clinical trials. Finally, in 1947, the Nuremberg Code laid down ten basic tenets for the protection of subjects and patients. Among other things, these provided for a voluntary declaration of consent by trial participants; the right of trial participants to comprehensive information on the nature, purpose, and potential risks of the experiment; and the right of trial participants to withdraw from the trial Eventually, from the mid-1970s, the FDA found it necessary to reject clinical research from other countries, since they felt that they didn't
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To read more and buy, visit http://shop.bsigroup.com/BIP0113 © BSI British Standards Institution have the same ethical and safety standards as the U.S. Europe and Japan each developed their own set of Good Clinical Practice (GCP) guidelines.
The specifics of medical devices
Laws specific to medical devices before the 1950s were few and far between as it was felt that there were few devices that offered appreciable risk to either the patients or the operators. However, the risks from infected devices and X-ray equipment were recognized and regulations based on the recommendations of the International Commission on Radiological Protection (ICRP), to protect excessive exposure to ionizing radiation, were implemented by a number of countries. Later in the 1960s regulations to control the sale of sterilized medical devices were introduced into the pre-existing legislation for drug safety in many countries. Throughout Europe, however, regulations varied significantly between the various countries.
Using the UK as an example, the rapid growth in the availability and complexity of medical equipment in the 1960s, resulted in product specialists being recruited to advise hospitals and to develop standards and purchasing specifications. In the late 1960s, the defect and adverse incident reporting system and the Scientific and Technical Branch (STB) of the Department of Health (DH) were established to improve the quality and safety of medical equipment along with a voluntary quality assurance system covering design and production.
Health care provision outside of the National Health System (NHS) was regarded as negligible and control of medical devices used in the NHS was seen as inadequate to protect public health. The main instrument of regulation was therefore instructions from the DH to Health Authorities and, in particular, the Supplies Officers to those authorities, that they should purchase only devices that conformed to an appropriate British (or comparable) Standard. Compliance with a standard was to be part of every purchasing contract and could therefore be enforced by civil contract law. Laws of general application, such as the Trades Descriptions Act 1968 and the Consumer Protection Act 1987 applied to such purchases in addition to contract laws.
The system was strengthened by the development of the Manufacturer Registration Scheme (MRS), which was launched in April 1982, and was a voluntary registration scheme initially for manufacturers of sterile medical devices and surgical products. The Supplies Technology Division and later the Medical Devices Directorate evaluated manufacturing practices of those who chose to register and carried out audits on manufacturers' quality systems. Manufacturers who were assessed as being satisfactory were named on the register that was issued to NHS Supplies Officers with a recommendation to buy from registered manufacturers whenever possible.
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The first of the guides to Good Manufacturing Practice were published in 1981 and this was followed by six others until by 1988 almost the entire field of medical devices was covered. As the scope of the scheme grew and the number of manufacturers on the register increased, it became difficult for non-registered manufacturers to sell to the NHS. In addition, being registered also became a useful indicator of quality when marketing to other countries. At its height, the MRS registered 580 manufacturing sites worldwide, but the scheme was disbanded in June 1998 when the Medical Devices Directive 93/42 became fully operational.
Harmonization
The lack of a coherent and consistent system for assessing the safety and efficacy of medical devices throughout Europe added substantial expense to the cost of selling devices in Europe and often acted as a technical barrier to trade within the various countries. It was therefore felt that a harmonized approach to creating safety standards across the member countries of the European Community was needed to remove such trade barriers and simplify the process of bringing medical devices to the markets of the member states. In 1985 it was therefore decided to gradually remove the product safety requirements of the individual countries and replace them with Essential Requirements (ERs) that would cover all of the European Economic Area (EEA).
In brief, the goal of the new regulations was to provide a vehicle whereby European legislation could be harmonized, product compliance with the ERs for safety and performance could be ensured, device safety, quality and performance could be improved, and trade barriers would be removed.
Prior to the 1990s each country had their own quality standard mark, such as the Kitemark of the BSI in the UK and the TÜV GS mark in Germany, and other countries either had the choice of accepting these marks as sufficient proof of suitability or could demand that they be tested by their own standards before allowing them to be marketed in the country. The development of the MDD and their application to the awarding of the European CE mark of quality, theoretically, removed national barriers and allowed such marked devices freely to enter any European market. In practice, however, there were initial teething problems with purchasers in some countries, such as Germany, demanding that the quality standard of their own country be displayed on a device in addition to the CE mark before they would consider buying it. When the European Union (EU) began to tighten up on such practices other tactics were used by some countries to maintain control of what they felt should enter the market. France, for example, developed legislation that would require a three-month pre-market declaration for certain high-risk medical devices that had already received a CE mark. Seven EU member
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Although such practices do still occur, the implementation of the directives and the establishment of the CE mark has been a major step forward in creating a safe, open and harmonious market in Europe and central to the award of CE mark certification for medical devices is proof of conformance to certain ERs.
The ERs for medical devices are set out in directives and, an important element of these ERs is risk management, which must be performed on all devices to provide an assessment of the inherent risks of the device in comparison with its benefits. 
